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Summary A phase I study was designed to assess whether dose intensity of an 'accelerated' cyclopho-
sphamide-doxorubicin-etoposide (CDE) regimen plus granulocyte colony-stimulating factor (G-CSF) could
be increased further, in an outpatient setting, by escalating the dose ofeach single drug of the regimen. Patients
with previously untreated small-cell lung cancer (SCLC) received escalating doses of cyclophosphamide (C)
1100- 1300 mg m-2 intravenously (i.v.) on day 1, doxorubicin (D) 50-60 mg m-2 i.v. on day 1, etoposide (E)
110-130 mg m-2 i.v. on days 1, 2, 3 and every 14 days for at least three courses. Along with chemotherapy,
G-CSF (filgastrim) 5 jug kg-1 from day 5 to day 11 was administered subcutaneously (s.c.) to all patients.
Twenty-five patients were enrolled into the study. All patients at the first dose level (C 1100, D 50, E 110 x 3)
completed three or more cycles at the dose and schedule planned by the protocol and no 'dose-limiting toxicity'
(DLT) was seen. At the second dose level (C 1200, D 55, E 120 x 3) three out of five patients had a DLT
consisting of 'granulocytopenic fever' (GCPF). Another six patients were treated at this dose level with the
addition of ciprofloxacin 500 mg twice a day and only two patients had a DLT [one episode of documented
oral candidiasis and one of 'fever of unknown origin' (FUO) with generalised mucositis]. Accrual of patients
proceeded to the third dose level (C 1300, D 60, E 130 x 3) with the prophylactic use ofciprofloxacin. Four out
of six patients experienced a DLT consisting of GCPF or documented non-bacterial infection. Accrual of
patients at the third dose level was then resumed adding to ciprofloxacin anti-fungal prophylaxis (fluconazole
100 mg daily) and anti-viral prophylaxis (acyclovir 800 mg twice a day) from day 5 to 11. Out of five patients
treated three experienced a DLT consisting of severe leucopenia and fever or infection. With a simultaneous
dose escalation and schedule acceleration it is indeed possible to take maximum advantage of G-CSF activity
and to increase CDE dose intensity by a factor 1.65 -1.80 for a maximum of 3 -4 courses. The role of anti-
microbial prophylaxis in this setting deserves to be investigated further.
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Combination chemotherapy is the mainstay of small-cell lung
cancer (SCLC) treatment (Idhe, 1992). Whereas an agreement
has been reached as to the optimal chemotherapy duration,
the importance of dose intensity is still being discussed.
However, at least part of the retrospective (Klasa et al., 1991)
and prospective (Arriagada et al., 1993) data available seem
to indicate a possible improvement in clinical outcome with
the increase of chemotherapy dose intensity. Cyclopho-
sphamide-doxorubicin-etoposide (CDE) is accepted world-
wide as one of the standard chemotherapy regimens in the
treatment of SCLC. This drug combination has also been
used successfully in other solid tumours (Somlo et al., 1994)
and haematological malignancies including non-Hodgkin's
lymphomas (Sparano et al., 1993) and myeloma (Ohrling et
al., 1993). The dose-limiting toxicity of CDE is myelosup-
pression, particularly neutropenia, with an incidence of
febrile neutropenia varying from 53% (Trillet-Lenoir et al.,
1993) to 77% (Crawford et al., 1993). The recent availability
of haemopoietic growth factors has fostered studies of CDE
dose intensification in SCLC. Randomised studies have
shown that both granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) (Hamm et al., 1994) and granulocyte
colony-stimulating factor (G-CSF) (Trillet-Lenoir et al., 1993;
Crawford et al., 1993) can reduce myelosuppression
associated with standard dose CDE chemotherapy in
SCLC, allowing full dose chemotherapy to be delivered on
time in the majority of patients. By using G-CSF or GM-
CSF prophylactically, an attempt to increase the dose
intensity of CDE beyond the standard has also been made.
We have shown that CDE chemotherapy can be delivered
every 2 weeks instead of the usual 3 weeks. This
chemotherapy 'acceleration' yields a 50% increase in the
projected CDE dose intensity (Ardizzoni et al., 1993).
Preliminary results from a multicentre randomised study
would indicate that 'accelerated' chemotherapy in SCLC may
result in a better clinical outcome (Steward et al., 1995). The
present phase I study was designed to evaluate whether dose
intensity of an accelerated CDE could be increased further by
escalating the dose of each single drug of the regimen. G-CSF
alone or combined with anti-microbial therapy has been used
to support CDE dose escalation, the aim being to assess the
maximum tolerated dose intensity and the dose-limiting
toxicity (DLT) of an outpatient CDE.
Patients and methods
Eligibility
Previously untreated patients with histologically or cytologi-
cally proven small-cell lung cancer, WHO performance status
<3, age <70 years and normal renal, hepatic and cardiac
function were eligible for the study. Other eligibility criteria
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included: no previous or concurrent malignancy; no other
serious medical or psychiatric illness which would preclude
informed consent or prevent the administration of an
intensive treatment. All patients gave their informed consent
according to national and institutional guidelines. The
prestudy work-up included complete history, physical
examination and recording of weight, height, performance
status and tumour stage. Computed tomography (CT) scan
of the thorax and brain, bone marrow biopsy, fibreoptic
bronchoscopy with biopsy, bone nuclear scan, upper abdo-
men CT scan or echography and ECG were performed in all
patients. Initial laboratory data obtained included complete
blood chemistries and blood cell count with differential, NSE
and CEA test. Patients with brain metastasis, those under
steroid treatment, those with fever >38°C or infection were
not eligible for the study.
Study design
A standard phase I study design was used to define the
'maximum tolerated dose' (MTD) of a CDE regimen
administered on an outpatient basis every 14 days. The
MTD was defined as the dose level at which the next higher
dose level produced a DLT in three or more of six patients.
A minimum of three patients were treated at each CDE
dose level and, if no DLT was seen, then subsequent patients
were treated at the next dose level. If one or two of three
No DLT
patients experienced a DLT, then three more patients were
entered at the same dose level and dose escalation proceeded
only if fewer than three of six patients experienced a DLT at
a given dose level. On the contrary, if three or more patients
experienced a DLT at any new dose level, no further dose
escalation was undertaken. No intrapatient chemotherapy
dose escalation was allowed. The DLTs were defined as
follows: (1) grade IV haematological toxicity lasting more
than 4 days; (2) grade IV thrombocytopenia at any duration
associated with bleeding or grade IV anaemia ofany duration
associated with cardiac failure; (3) grade IV non-haematolo-
gical toxicity (other than alopecia and vomiting); (4)
granulocytopenic fever (GCPF) (granulocytes<0.5 x 09 1-'
or WBC< 1.0 x 109 1-1 with at least one episode of
fever>38.2°C); (5) clinically or microbiologically documen-
ted infection requiring anti-microbial parenteral therapy; (6)
fever (>38.20C) of unknown origin (FUO), regardless of the
WBC count, lasting more than 3 days and requiring anti-
microbial parenteral therapy; (7) no haematological recovery
by day 21.
Treatment
The starting dose level of CDE consisted of cyclopho-
sphamide (C) 1100 mg m2 i.v. on day 1, doxorubicin (D)
50 mg m-2 i.v. on day 1, etoposide (E) 110 mg m-2 i.V. on
days 1, 2 and 3. At the second dose level patients had to
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Figure 1 Study design.
-1 . - --.receive C 1200 mg m-2, D 55 mg m-2, E 120 mg m-2 x 3
and, at the third level, C 1300 mg m-2, D 60 mg m-2, E
130 mg m-2 x 3. All patients received G-CSF (filgastrim) at
the dose of 5 ig kg - self-administered s.c. from day 5 to day
11. If GCPF or infection were found as the DLT, the
protocol established that another cohort of patients at the
same dose level would have been treated with the addition of
anti-microbial prophylaxis from day 5 to day 11, assuming
GCPF was caused by occult bacterial, fungal or viral
infection (Figure 1). Anti-microbial prophylaxis had to
consist of ciprofloxacin 500 mg twice a day, fluconazole
100 mg and acyclovir 800 mg twice a day (Table I).
Chemotherapy courses were repeated every 14 days
if complete haematological recovery occurred
(WBC>3.0x 1091-
1 or granulocytes>2.Ox l091-1, plat-
lets> 100 x l09 1-1 and in the absence of any more than
grade I non-haematological toxicity. In the case of an
inadequate recovery from toxicity, patients were rechecked
daily in order to resume treatment as soon as clinical and
haematological conditions permitted. Chemotherapy had to
be given for a minimum of three courses. No dose escalation
was permitted until all the patients in the previous dose level
had completed three courses of treatment.
No dose reduction was foreseen; if a DLT ocurred, the
patient had to be removed from the study and to continue
the treatment with a standard CDE (C 1000 mg m-2 day 1,
D 45 mg m-2 day 1 and 100 mg m-2 days 1, 2 and 3 every
21 days).
Patients who did not experience DLTs during the first
three cycles were offered one or two more cycles of therapy.
As supportive therapy, all patients with granulocytes
<0.5 x I09 l-I were given oral antibiotic prophylaxis with
ciprofloxacin 500 mg twice a day and fluconazole 100 mg
daily. In the case of GCPF, FUO or documented infection,
an outpatient empirical antibiotic therapy consisting of
ceftazidime 1 g three times a day intramuscularly was
started. Packed RBCs were administered with Hb
levels<8 g 1-1 and platelets were transfused to maintain a
platelet count > 15 x 109 1- l1.
Patient evaluation andfollow-up
During treatment complete blood cell counts and differentials
were obtained every other day. In case a grade IV
haematological toxicity was documented, blood counts were
performed daily until recovery of grade IV toxicity. Clinical
examination, recording of toxicity, performance status,
weight and blood chemistry were performed before starting
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each chemotherapy cycle.
Patients were instructed to measure their axillary body
temperature at least three times a day. In case of fever
>38.2°C they had a contact their physician as soon as
possible. At the hospital, axillary temperature was taken
again and a complete blood count obtained; if the
temperature was >38.2°C and the granulocytes were
<500 ml - the patient was considered as having a GCPF.
In this case routine cultures of blood, urine and other
suspected sources were performed and empirical parenteral
antibiotic treatment started. Evaluation of response was due
after three cycles with CT scan of thorax and repetition of all
previously positive tests. Patients with limited disease,
achieving partial or complete response, received thoracic
radiotherapy and only those in complete response were
enrolled into a prospective multicentre randomised study of
prophylactic cranial irradiation.
Response criteria and dose intensity calculation
Standard WHO criteria for response and toxicity evaluation
were used (Miller et al., 1981). Dose intensity was expressed
in mg m-2 day-1 and calculated according to Hryniuk and
Bush (1984). As reference standard regimen to calculate the
'relative' dose intensity (RDI) planned at each dose level, a
standard dose intensity CDE (C 1000 mg m-2, D 45 mg m-2,
E 100x3 mg m-2 every 21 days) was used. The reported
dose intensity was the average (ARDI) of the three drugs
used (C, D and E). The increase over the standard in the
planned dose intensity at each dose level has been calculated
as follows:
Dose m-2 at a given dose level x 3 (No. of planned courses)
No. of weeks elapsing between the first and the third course-
Standard dose m-2 x 3
No. of weeks elapsing between the first and the third course
As an example, the increase in cyclophosphamide dose
intensity at the first dose level is reported:
1100 x 3 1000 x 3 4 : 6 = 825: 500 = 1.65
4 6
The actual dose intensity was calculated at the third and at
the fourth cycle. All patients were considered for actual dose
intensity analysis including the patients who had to stop
Table I Dose escalation programme
First level Second level Second level (b) Third level Third level (b)
Cyclophosphamidea 1100 1200 1200 1300 1300
(mg m-2 day 1)
Doxorubicina 50 55 55 60 60
(mg m 2 day 1)
Etoposidea 110 120 120 130 130
(mg m-2 days 1 -3)
Filgastrim Yes Yes Yes Yes Yes
(5 jtg kg-' days 5- 11)
Ciprofloxacin No No Yes Yes Yes
(500 mgx2 days 5-11)
Fluconazole No No No No Yes
(100 mg days 5- 11)
Acyclovir No No No No Yes
(800 mgx 2 days 5-11)
Dose intensity (DI) 65% 80% 80% 95% 95%
increaseb
aCycles ofchemotherapy repeatedevery 14days. bIncrease in planned DI compared with a standard CDE (C 1000, D45, E 100 x 3 every21 days).
See 'Patients and methods' for the calculation ofdose-intensity increase.Intensified CDE in SCLC
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treatment before the third or the fourth cycle. In these
patients the total dose of chemotherapy received was divided
by the time required to complete three or four cycles of
therapy (4 and 6 weeks respectively), regardless of the
number of courses actually received.
Results
From February 1992 to June 1994 25 SCLC patients were
enrolled into the study. Patient characteristics are shown in
Table II. A total of 73 cycles, with a median of three (range
1-5) cycles per patient, were administered according to
protocol.
Dose-limiting toxicity
All the three patients enrolled at the first dose level completed
three or more cycles of chemotherapy at the dose and
schedule planned by the protocol and no DLT was seen.
Table II Patient characteristics and response to treatment
No. of patients 25
Median age (range) 58 (41 -69)
Sex (M/F) 21/4
Median PS (range) 0 (0- 1)
Stage
LD 12
ED 13
Response
CR 8
PR 13
NE 4a
aOne patient treated as adjuvant therapy after surgery, one patient
lost to follow-up before evaluation and two patients died before
evaluation.
At the second dose level, three out of five patients had a
DLT. Two had GCPF after the first or second cycle and one
had GCPF with a clinically documented infection (dental
abscess) after the second cycle. However, the duration of
GCPF was only 1 day in all the patients and no systemic
infection was documented.
According to the protocol, the enrolment of patients was
resumed at the same dose level adding prophylactic
antibiotics consisting of ciprofloxacin 500 mg twice a day
from day 5 to 11. Six more patients were treated at this dose
level and only two had a DLT. One patient had a
microbiologically documented infection (oral candidiasis)
after the second cycle and one patient had one episode of
FUO lasting for 6 days associated with stomatitis and
balanoproctitis after the third cycle. The second dose level,
with the addition of prophylactic ciprofloxacin, was therefore
considered feasible and patient accrual proceeded to the third
dose level using ciprofloxacin in adjunct to G-CSF
prophylaxis. Four out of six patients experienced a DLT.
One patient had GCPF and a microbiologically documented
infection (oral candidiasis) after the first cycle; another had a
thoracic herpes zoster infection without GCPF after three
cycles; the third developed GCPF before the second cycle;
and the last patient had GCPF with generalised mucositis
(stomatitis and balanoproctitis) during the second cycle.
Based on the observation that, with the addition of
ciprofloxacin prophylaxis, all documented infections seen in
our study were non-bacterial, another cohort of patients was
treated at the third dose level adding to ciprofloxacin anti-
fungal (fluconazole 100 mg daily) and anti-viral (acyclovir
800 mg twice a day) prophylaxis from day 5 to 11. Five more
patients were accrued ofwhich three experienced a DLT. One
patient had GCPF and a clinically documented infection
(pneumonia) after the second cycle; he died 20 days later with
leucocytosis (WBC=56.0x l01-') and multiple cerebral
ischaemic lesions revealed at brain CT scan. Another patient
had grade IV leucopenia lasting for 5 days along with grade
IV thrombocytopenia requiring platelet transfusion and
hospital admission for 6 days. The third patient with DLT
had GCPF without documented infection during the third
course (Table III).
Table III Results
No. of No. ofdays with
Patients courses GCPF GCPF or FUO Infection DLT
1 5 0
First level 2 3 - 0
3 4 0
4 4 0
5 3 0
Second level 6 2 Yes 1 - GCPF
7 1 Yes 1 - GCPF
8 2 Yes 1 Dental abscess GCPF/INF
9 4 0
10 4 0
11 3 0
Second level (b) 12 3 Yes 1 Oral candidiasis GCPF/INF
13 3 0
14 3 6 FUO/mucositisa FUO
15 2 Yes 3 Oral candidiasis GCPF/INF
16 3 0
17 4 0
Third level 18 4 0 Zoster INF
19 1 Yes 1 - GCPF
20 2 Yes 2 Mucositisa GCPF
21 3 0
22 2 Yes 2 Pulmonary GCPF/NF
23 1 0 WBC IV
Third level 24 3 Yes 2 - GCPF
25 4 0
FUO, fever of unknown origin; WBC IV, grade IV leucopenia for 5 days; INF, infection; GCPF, granulocytopenic fever. aStomatitis and
balanoproctitis.Intensified CDE in SCLC
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Other toxicities
The nadir haematological toxicity is shown in Table IV. At
the first dose level no patient developed grade IV toxicity. At
the second and third dose levels 22.5% and 31% of cycles
produced grade IV leucopenia whose median duration was 2
(range 1-4) and 3 (range 1-5) days respectively. The median
WBC, Hb and platelet nadirs tended to worsen with dose
escalation but remained relatively constant throughout the
first three cycles. Only one patient required platelet
transfusion after the first cycle and no RBC transfusion
had to be given during the first three cycles. Four patients
out of eight who continued chemotherapy beyond the third
cycle required RBC transfusions for the occurrence of
k grade 3 anaemia. Non-haematological toxicity was mild
and in no instance did it exceed grade II with the exception
of the two cases of generalised mucositis mentioned above.
Particularly, no case of significant cardiac, renal or hepatic
toxicity was reported.
Dose intensity
At all dose levels the median interval between cycles was 14
days (range 14-21 days). The percentages of cycles delivered
on day 15, as scheduled by the protocol, at the three dose
levels were 100%, 58% and 56% respectively. No dose
reduction was applied. Seventeen patients were able to
complete the planned three courses. Among these, seven
and one patients, respectively, were given one and two more
courses (Table III).
The median percentages of actually delivered vs planned
dose intensity, calculated for all patients at the third cycle,
were 96%, 85%, 82% in the three dose levels respectively. At
the fourth cycle, they were 85%, 75% and 71% respectively.
Response and survival
Results in terms of objective response to treatment are
reported in Table II. Four patients were not evaluable for
response. One patient received chemotherapy as adjuvant
treatment after surgery. One patient was lost to follow-up
and two others died before response evaluation. Out of 21
evaluable patients there were eight complete responses and 13
partial responses. Median time to progression and median
overall survival, calculated according to the method of
Kaplan and Meier, were 44 and 68 weeks respectively.
Discussion
Since the demonstration of the important role played by dose
intensity in the treatment outcome of a number of drug-
sensitive tumours (Gurney et al., 1993) and the availability
for clinical use of haemopoietic growth factors, phase I-II
studies of chemotherapy intensification have abounded
(Bronchud, 1993). The primary objective of these studies
was to assess whether haemopoietic growth factors, by
ameliorating chemotherapy haematological toxicity, were
able to allow chemotherapy dose intensification. Increase of
dose intensity above that of standard chemotherapy can be
accomplished with both dose escalation and schedule
acceleration. Since the main effect of GM- and G-CSF is in
accelerating neutrophil recovery, and only to a lesser extent
in reducing the severity of neutrophil nadir, we first aimed at
verifying the possibility of accelerating chemotherapy
administration. In a study of 15 SCLC patients we were
able to deliver a CDE regimen, at standard doses, combined
with GM-CSF every 2 weeks as opposed to the usual 3
weeks, resulting in a 50% projected dose intensity escalation
(Ardizzoni et al., 1993). Two subsequent randomised trials
confirmed that such an acceleration was not possible in the
absence of the use of GM-CSF (Ardizzoni et al., 1994;
Pennella et al., 1995). The DLT of accelerated chemotherapy
is cumulative thrombocytopenia which becomes severe,
requiring platelet transfusions, after the fourth cycle and
often precludes the completion of treatment.
In the present study we aimed at identifying the maximum
tolerated dose intensity by exploring the feasibility of dose
escalating a CDE regimen repeated at 2 week intervals on an
outpatient basis for at least three courses. The decision to
administer a fourth course of therapy was left open and was
indeed taken, with no serious adverse events, in the majority
of patients who did not develop a DLT. This number of
courses seems adequate in the treatment of SCLC based on
the results of a recent randomised British study (Bleehen et
al., 1993).
Given the definition of DLT used in our study, the MTD
turned out to be the first dose level (C 1l1O mg m-2, D
50 mg m-2, E 110 mg m-2 x 3) which corresponds to a 65%
projected dose intensity increase compared with a standard
every 21 days CDE. This poor level of dose escalation, even
in the presence of G-CSF support, is not surprising since a
number of other phase I studies, most of which used GM-
CSF as a haemopoietic growth factor, came to a similar
conclusion in SCLC (Paccagnella et al., 1993), breast
(Hoekman et al., 1991), ovarian (Rusthoven et al., 1991)
and urothelial cancer (Scher et al., 1992). The lack of a
significant impact of myelocytic growth factors on the depth
of neutrophil nadir may account for this result.
At the second dose level three of five patients developed
GCPF. However, GCPF lasted only 1 day in all patients and
in no instance did it require parenteral antibiotic treatment or
hospitalisation. Therefore, using less strict criteria for
defining a DLT, the second dose level, corresponding to an
80% projected dose intensity increase, might also be
considered feasible. This amount of dose intensity increase
is probably the maximum achievable on an outpatient basis,
with a strategy of combined dose escalation and schedule
acceleration using haemopoietic growth factors as the only
supportive treatment. Further dose intensification is hindered
by the development of GCPF and infection.
The efficacy of antibiotic prophylaxis in preventing
infections in patients undergoing conventional chemotherapy
for solid tumours is still 'sub judice'. Previous trials of
prophylactic cotrimoxazole as adjunct to chemotherapy of
SCLC have shown moderate benefit in reducing the infection
rate (Figueredo et al., 1985; de Jongh et al., 1983).
Quinolones have been found to be more effective than
cotrimoxazole in the prevention of infectious complications in
the treatment of haematological malignancies (Dekker et al.,
1987). As yet no such study is available for solid tumours.
In our study, the addition of ciprofloxacin at the second
Table IV Nadir haematological toxicity
Media WBC x 109 r1 Media Hb g dt' Median platelets x 1091-l
(range) (range) (range)
Cycles 1 2 3 1 2 3 1 2 3
First level 3.0 2.0 2.1 12.8 12.3 12.1 140 120 100
(1.4-3.4) (1.2-2.9) (2.0-2.5) (12.6-13.5) (11.5-12.5) (9.5-12.5) (115-180) (100-148) (98-150)
Second level 1.5 0.9 1.8 11.5 10.1 9.3 100 88 85
(0.5-2.9) (0.3- 1.8) (0.8-2.8) (8.6-13.8) (8.2-13.5) (7.5-13.5) (30-280) (56- 173) (65-140)
Third level 1.0 1.2 1.8 12.1 10.8 10.3 98 101 118
(0.4-2.1) (0.3- 1.5) (0.5-2.1) (9.1 -14.5) (7.8- 12.4) (8.2- 11.1) (9-184) (40-203) (80-202)
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dose level almost abrogated the occurrence of GCPF. The
small number of patients does not allow us to draw firm
conclusions on the role of quinolone prophylaxis in this
setting. However, since GCPF remains the dose-limiting
toxicity of dose-intensified CDE, despite the use of G-CSF,
the efficacy of antibiotic prophylaxis in conjunction with
haemopoietic growth factors deserves further exploration
with specific trials. Given the increasing prevalence of Gram-
positive infection in patients receiving prophylactic quino-
lones (Meunier, 1990), ciprofloxacin alone may not be the
optimal antibiotic treatment and the combination of
ciprofloxacin with other agents such as vancomycin,
rifampicin or roxithromycin is currently advocated (Archim-
baud et al., 1991). Most patients receiving G-CSF plus
ciprofloxacin at the second and third dose level developed
non-bacterial infections or mucositis. Both fluconazole and
acyclovir have been found to be effective in preventing,
respectively, fungal and viral infections in patients under-
going intensive anti-neoplastic therapy for the treatment of
haematological malignancies (Wade et al., 1984; Winston et
al., 1993). Despite the use of anti-mitotic and anti-viral
prophylactic therapy, the third dose level did not appear
feasible in our study owing again to the occurrence of severe
leucopenia and fever. However, none of the patients
developed mucositis or oral candidiasis, which, on the
contrary, was frequently observed in previous patient
cohorts where no anti-fungal or anti-viral prophylaxis was
used. Also this observation, owing to the small sample size
and to the type of study design, only permits one to
hypothesise on the possible role of fluconazole and acyclovir
prophylaxis in moderately dose-intensive treatments for solid
tumours which would need to be addressed with more
appropriate studies.
In conclusion, with a simultaneous dose escalation and
schedule acceleration it is indeed possible to take maximum
advantage of G-CSF activity and to increase CDE dose
intensity by a factor 1.65-1.80 for a maximum of 3-4
courses. The next step is to assess the impact of such a dose
intensity increase on the treatment outcome of SCLC
patients. A randomised prospective study comparing
standard CDE vs CDE at the MTD identified in the present
study is presently ongoing in Europe. The study is also
designed to address the role of antibiotic prophylaxis in this
setting (Tjan-Heijnen et al).
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